Clinical trials: Proteus Infections
Infection, E Coli Infections
Community - Associated Extended-spectrum Beta-lactamases (ESBL)
The purpose of this study is to review patients with E. coli infections at the University of Pittsburgh Medical Center (UPMC) from September 1, 2006 to August 31, 2007 to determine if these infections have arisen in the community…
- Conditions
- Infection, E Coli Infections, Klebsiella Infections, Proteus Infections
- Trial name
- NCT00363220
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Pittsburgh
Solid Tumor, Adult
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Shenzhen)
This trial will enroll 47 subjects who will be be treated with the IBA PROTEUS® PLUS Proton Beam radiation Therapy (PBT) medical device.
- Trial name
- NCT07153094
- Testing
- Proton Beam Therapy (PBT)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Ion Beam Applications
Coronary Heart Disease
PROTEUS: Evaluating the Use of Artificial Intelligence to Support Stress Echocardiography Testing for Heart Disease
PROTEUS is a multicentre, two arm, randomised controlled trial of a medical device to assess the impact of the introduction of EchoGo into the standard care pathway for stress echocardiology.
- Trial name
- PROTEUS (NCT05028179)
- Testing
- EchoGo
- Where
- 20 sites in United Kingdom
- Volunteers
- 2,338 people
- Sponsor
- Ultromics Ltd
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome
Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)
This is an open label, Phase 1/2 study of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha (PIK3CA)-related Overgrowth…
- Trial name
- MOSAIC (NCT03094832)
- Testing
- Miransertib
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 50 people
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Proton Therapy, Radiation Therapy, Secondary Skin Reactions
Protoacoustic Imaging For 3D Mapping
The purpose of this study is to test a new imaging technology called radioacoustic imaging (RAI) that may help doctors see where radiation is being delivered during proton therapy.
- Conditions
- Proton Therapy, Radiation Therapy, Secondary Skin Reactions, Liver Cancer, Prostate Cancer
- Trial name
- NCT07832617
- Testing
- Radiacoustic Imaging w/Ultrasound.
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Oklahoma
Hypertension, Diabetes Mellitus, Type 2
Proteus Discover in Subjects With Uncontrolled Hypertension and Type 2 Diabetes
The purpose of this study was to evaluate the efficacy of a new digital health offering, Proteus Discover to lower blood pressure and glycated hemoglobin in patients with uncontrolled hypertension and type 2 diabetes.
- Conditions
- Hypertension, Diabetes Mellitus, Type 2, Hypercholesterolemia
- Trial name
- NCT02827630
- Testing
- Proteus Discover, Usual Care
- Volunteers
- 118 people
- Sponsor
- Proteus Digital Health, Inc.
Proteus Syndrome
Dose Finding Trial of MK-7075 in Children and Adults With Proteus Syndrome
Background: Proteus syndrome (PS) is caused by a mutation in the AKT1 gene. This gene makes a protein that communicates with other proteins in the body to make cells grow.
- Trial name
- NCT02594215
- Testing
- MK-7075 (miransertib)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Escherichia Coli Bacteremia, Klebsiella Bacteraemia
Switch to Oral Antibiotics in Gram-negative Bacteremia
Eligible subjects will be those age 18 years or more with mono-microbial blood stream infection caused by E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, or Proteus species, who have…
- Conditions
- Escherichia Coli Bacteremia, Klebsiella Bacteraemia, Enterobacter Bacteraemia, Serratia Bacteraemia
- Trial name
- SOAB (NCT04146922)
- Testing
- Step down to oral antimicrobial therapy, IV antimicrobial therapy
- Where
- 7 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 176 people
- Sponsor
- Hamad Medical Corporation
Solid Tumor, Adult
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Sichuan)
This trial will enroll 47 subjects who will be be treated with the IBA PROTEUS® PLUS Proton Beam radiation Therapy (PBT) medical device.
- Trial name
- NCT07152353
- Testing
- Proton Beam Therapy (PBT)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Ion Beam Applications
Proteus Syndrome
MK-7075 (Miransertib) in Proteus Syndrome
Background: Proteus syndrome is a rare overgrowth disorder. Most people begin to have symptoms between 6 months and 2 years of age. There are very few living adults with this disease. There is also no known treatment for it.
- Trial name
- NCT04316546
- Testing
- MK-7075 (miransertib)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Detection Accuracy, Patient Compliance
Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients
The main purpose of this exploratory trial is to evaluate the reliability, safety and usability of the Transplantation Sensor System when the Ingestible Event Marker (IEM) is given in combination with ECMPS 360 mg tablets in…
- Trial name
- NCT01320358
- Testing
- ECMPS-IEM
- Where
- 5 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Regurgitation
VenusP-Valve Pivotal Study (PROTEUS STUDY)
A prospective, multi-center, non-randomized interventional study to evaluate the safety and effectiveness of the VenusP-ValveTM System in patients with native right ventricular outflow tract (RVOT) dysfunction.
- Trial name
- PROTEUS (NCT06010563)
- Testing
- Transcatheter pulmonary valve implantation (TPVI), VenusP-ValveTM System
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Venus MedTech (HangZhou) Inc.
PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome (PS)
A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)
This is a study of the safety and tolerability of oral miransertib (MK-7075) administered to participants at least 2 years of age with phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA)-related…
- Trial name
- NCT04980872
- Testing
- Miransertib
- Where
- 11 sites in United States, Australia and 3 more
- Volunteers
- 60 people
- Sponsor
- Merck Sharp & Dohme LLC
Proteus Syndrome, PIK3CA Related Overgrowth Spectrum
Study of Proteus Syndrome and Related Congenital Disorders
This study will examine rare congenital disorders that involve malformations and abnormal growth. It will focus on patients with Proteus syndrome, whose physical features are characterized by overgrowth, benign tumors of fatty…
- Trial name
- NCT00001403
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Solid Tumor, Adult
Clinical Trial of the Safety and Efficacy of IBA Proton Therapy System PROTEUS® PLUS (Hebei)
This trial will enroll 47 subjects who will be be treated with the IBA PROTEUS® PLUS Proton Beam radiation Therapy (PBT) medical device.
- Trial name
- NCT07137195
- Testing
- Proton Beam Therapy (PBT)
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Ion Beam Applications
Type 2 Diabetes Mellitus
Proteus Sustained Behavior Change Study
The study will test whether the Proteus Sustained Behavior Change (SBC) System will help Type 2 diabetics feel more able to perform self-care activities, feel less distressed about diabetes, and reduce mean fasting blood glucose…
- Trial name
- NCT01503008
- Testing
- Proteus Sustained Behavior Change system, Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)
- Where
- 2 sites in United States
- Sponsor
- Proteus Digital Health, Inc.
High Risk Proliferative Diabetic Retinopathy
Prospective, Randomized, Multicentre, Open-label, Phase II / III Study to Assess Efficacy and Safety of Ranibizumab 0.5 mg Intravitreal Injections Plus Panretinal Photocoagulation (PRP) Versus PRP in Monotherapy in the Treatment of Subjects With High Risk Proliferative Diabetic Retinopathy.
This study is a prospective, randomized, multicentre, open label study that intents to compare the efficacy and safety of ranibizumab 0.5 mg Intravitreal (ITV) injections plus Panretinal Photocoagulation versus Panretinal…
- Trial name
- PROTEUS (NCT01941329)
- Testing
- Panretinal Photocoagulation (PRP), Intravitreous injection of ranibizumab
- Where
- 13 sites in France, Italy and 2 more
- Volunteers
- 94 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
HIV
Digital Health Feedback System for Longitudinal Measurement of Medication Adherence During Anti-Retroviral (ARV)Therapy
This study uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new Proteus Digital Health (PDH) technologies approved by the FDA, to collect information about patients taking their ARV…
- Trial name
- NCT02800655
- Testing
- Digital Health Feedback System
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- University of California, San Diego
Proteus Mirabilis Infection, Bacteremia
Bloodstream Infection of Carbapenem-Resistant Proteus Mirabilis
This study aims to determine the clinical characteristics, risk factors, and resistance mechanisms of patients with carbapenem-resistant P. mirabilis bacteremia.Patients with P.
- Conditions
- Proteus Mirabilis Infection, Bacteremia, Carbapenem Resistant Bacterial Infection
- Trial name
- NCT06542965
- Testing
- Non-Interventional Research
- Where
- Turkey (Türkiye)
- Volunteers
- 67 people
- Sponsor
- Dokuz Eylul University
Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS)
Expanded Access to Provide ARQ 092 for the Treatment of Overgrowth Diseases and/or Vascular Anomalies
ARQ 092 is being investigated for patients with overgrowth diseases and/or vascular anomalies with genetic alterations of the PI3K/AKT pathway and may be available for patients who are ineligible for an ongoing ARQ 092 clinical…
- Conditions
- Proteus Syndrome, PIK3CA-Related Overgrowth Spectrum (PROS), Growth Disorders
- Trial name
- NCT03317366
- Testing
- ARQ 092
- Sponsor
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)